Verismo Therapeutics is a clinical-stage cell therapy company developing a multi-chain KIR-CAR platform that adapts NK-cell killer immunoglobulin-like receptor and DAP12 signaling to extend CAR T cell therapy beyond blood cancers into solid tumors. Founded by inventors of the Kymriah CAR-T (including Carl June), the company is advancing two Phase 1 programs: SynKIR-110 in mesothelin-positive solid tumors and SynKIR-310 in relapsed/refractory B cell non-Hodgkin lymphoma. It is a U.S. subsidiary of KOSDAQ-listed HLB Innovation.
1
Round
5
Tags
Apr 15, 2026
Latest raise
Funding activity · 1 round
Apr 15, 2026
$28M
Series B
Led by HLB Innovation
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
